ClinicalTrials.gov
public full text
Public Domain
Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.
The purpose of the study is to determine the extent of cyclosporine microemulsion dose reduction required to maintain stable renal function in maintenance cardiac transplant recipients, after initiation of everolimus.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients#881054
- Pharmacokinetic Study on the Combination of Everolimus-Tacrolimus#969866
- Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients#851649
- Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients With New Onset Diabetes After the 3rd Month Post-transplant#377336
- Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients#1072319
Record · ID 918371
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive